We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current RNAZ market cap is 5.02M. The company's latest EPS is USD -26.6376 and P/E is -0.27.
Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Operating Income | -5.33M | -4.06M | -3.29M | -5.11M | -2.17M |
Net Income | -5.3M | -4.09M | -3.33M | -5.19M | -2.32M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Operating Income | -457k | -726k | -6.15M | -18.67M | -19.42M |
Net Income | -607k | -2.34M | -6.84M | -17.57M | -18.55M |
Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 10.23M | 5.17M | 7.29M | 4.83M | 3.94M |
Total Liabilities | 5.79M | 3.53M | 2.71M | 3.5M | 2.28M |
Total Equity | 4.44M | 1.64M | 4.58M | 1.32M | 1.65M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 204k | 1.06M | 22.94M | 7.59M | 5.17M |
Total Liabilities | 1.31M | 4.46M | 2.53M | 4.35M | 3.53M |
Total Equity | -1.11M | -3.41M | 20.4M | 3.24M | 1.64M |
Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -12.41M | -18.07M | -3.94M | -6.28M | -10.19M |
Investing | -35k | -36k | -4k | -8k | -21k |
Financing | 14.93M | 15.91M | 6.09M | 6.87M | 9.32M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -509k | -493k | -5.27M | -15.76M | -18.07M |
Investing | N/A | N/A | -252k | -101k | -36k |
Financing | 500k | 1.12M | 25.52M | 5k | 15.91M |
Market Cap | 5.02M |
Price to Earnings Ratio | -0.27 |
Price to Sales Ratio | 0 |
Price to Cash Ratio | 1.81 |
Price to Book Ratio | 3.06 |
Dividend Yield | - |
Shares Outstanding | 696.23k |
Average Volume (1 week) | 30.48k |
Average Volume (1 Month) | 432.34k |
52 Week Change | -96.59% |
52 Week High | 264.00 |
52 Week Low | 6.6332 |
Spread (Intraday) | 1.62 (20%) |
Company Name | TransCode Therapeutics Inc |
Address |
1209 orange street wilmington, delaware 19801 |
Website | https://www.transcodetherapeutics.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions